Levofloxacin
Back to searchMolecule Structure
Scientific Name
Levofloxacin
Description of the Drug
Levofloxacin is a fluoroquinolone antibiotic used to treat infections caused by susceptible bacteria of the upper respiratory tract, skin and skin structures, urinary tract, and prostate, as well as for post-exposure treatment of inhaled anthrax and the plague.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB01137
http://www.drugbank.ca/drugs/DB01137
Brand Name(s)
Evoxil, Floxacin, Iquix, Levaquin, Levofloxacin, Oftaquix, Quinsair, Quixin, Tavanic
Company Owner(s)
Inforlife Sa, Jubilant Generics Ltd, Macleods Pharmaceuticals Ltd, Watson Laboratories Inc, Santen Inc, Mylan Pharmaceuticals Inc, Mylan Asi Llc, Emcure Pharmaceuticals Ltd, Zydus Pharmaceuticals Usa Inc, Akorn Operating Co Llc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Topoisomerase IV | PROTEIN COMPLEX | INHIBITOR | CHEMBL2363033 |
| DNA gyrase | PROTEIN COMPLEX | INHIBITOR | CHEMBL2311225 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL15397 | ||
| PharmGKB | PA450214 | ||
| Human Metabolome Database | HMDB0001929 | ||
| DrugBank | DB01137 | ||
| PubChem: Thomson Pharma | 14901428 | 14876841 | |
| PubChem | 149096 | 6956357 | |
| Mcule | MCULE-2011834955 | MCULE-1927163841 | |
| LINCS | LSM-5270 | ||
| Nikkaji | J142.436J | ||
| PDBe | LFX | ||
| BindingDB | 50366826 | ||
| EPA CompTox Dashboard | DTXSID0041060 | ||
| DrugCentral | 1569 | ||
| Brenda | 229614 | 11274 | 229615 |
| ChemicalBook | CB93569251 | CB4122906 | CB72567531 |
| Guide to Pharmacology | 10911 | ||
| rxnorm | LEVOFLOXACIN ANHYDROUS | LEVOFLOXACIN | LEVAQUIN |
| PubChem: Drugs of the Future | 12014081 | ||
| KEGG Ligand | C07660 | ||
| ChEBI | 63598 | ||
| ZINC | ZINC000000538273 |
